Logo for PAVmed Inc

PAVmed Investor Relations Material

Latest events

Logo for PAVmed Inc

Q1 2024

PAVmed
Logo for PAVmed

Q1 2024

14 May, 2024
Logo for PAVmed

Q4 2023

27 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from PAVmed Inc

Access all reports
PAVmed Inc. holds interests in various medical device technologies at various stages of development. Its initial pipeline includes: carPIX, a technology that transforms the humble stethoscope into a highly effective imaging tool; EsoGuard/EsoCheck, a novel, multi-marker screening test for esophageal cancer and Barrett's esophagus; PortIO, an implantable intraosseous vascular access device that could revolutionize the way patients needing vascular access are treated. NextCath, a revolutionary self-anchoring catheter technology based on an internally developed platform that eliminates the need for sutures or tissue adhesives to secure a catheter to the body; and NextVessel, which is being developed by NextCath Inc., and is designed to provide early detection of coronary atherosclerosis and other vascular conditions. PAVmed Inc. was founded in 2014 and is headquartered in New York, New York.